Literature DB >> 23092189

Progressive multifocal leukoencephalopathy: why gray and white matter.

Sarah Gheuens1, Christian Wüthrich, Igor J Koralnik.   

Abstract

Since it was first described in 1958, progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the brain caused by the polyomavirus JC (JCV), has evolved tremendously. It was once considered a noninflammatory disease that affected exclusively oligodendrocytes and astrocytes in the white matter of immunosuppressed individuals and was almost always fatal. Today, we understand that PML can present during the course of an immune reconstitution inflammatory syndrome and that it affects a broader range of individuals, including patients with minimal immunosuppression and those who are treated with novel immunomodulatory medications. Furthermore, JCV-infected glial cells are frequently located at the gray matter-white matter junction or within the gray matter, causing demyelinating lesions within cortical areas. Finally, JCV variants can also infect neurons, leading to the recognition of two distinct clinical entities: JCV granule cell neuronopathy and JCV encephalopathy.

Entities:  

Mesh:

Year:  2012        PMID: 23092189     DOI: 10.1146/annurev-pathol-020712-164018

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  52 in total

1.  Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells.

Authors:  Biswa Nath Sharma; Manfred Marschall; Christine Hanssen Rinaldo
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Analysis of JC virus DNA replication using a quantitative and high-throughput assay.

Authors:  Jong Shin; Paul J Phelan; Panharith Chhum; Nazym Bashkenova; Sung Yim; Robert Parker; David Gagnon; Ole Gjoerup; Jacques Archambault; Peter A Bullock
Journal:  Virology       Date:  2014-08-24       Impact factor: 3.616

3.  Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.

Authors:  Ivan Jelcic; Benoit Combaluzier; Ilijas Jelcic; Wolfgang Faigle; Luzia Senn; Brenda J Reinhart; Luisa Ströh; Roger M Nitsch; Thilo Stehle; Mireia Sospedra; Jan Grimm; Roland Martin
Journal:  Sci Transl Med       Date:  2015-09-23       Impact factor: 17.956

4.  Hyperperfusion in progressive multifocal leukoencephalopathy is associated with disease progression and absence of immune reconstitution inflammatory syndrome.

Authors:  Michael N Khoury; Sarah Gheuens; Long Ngo; Xiaoen Wang; David C Alsop; Igor J Koralnik
Journal:  Brain       Date:  2013-10-01       Impact factor: 13.501

5.  Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.

Authors:  Christian Wüthrich; Bogdan F Gh Popescu; Sarah Gheuens; Michael Marvi; Ronald Ziman; Stephen Pojen Denq; Mylyne Tham; Elizabeth Norton; Joseph E Parisi; Xin Dang; Claudia F Lucchinetti; Igor J Koralnik
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

6.  ABO blood groups and risk for progressive multifocal leukoencephalopathy.

Authors:  Michael N Khoury; Murray A Mittleman; Igor J Koralnik
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

7.  No reactivation of JCV and CMV infections in the temporal cortex and cerebellum of sporadic Creutzfeldt-Jakob disease patients.

Authors:  Judith Löffler; Susanne Krasemann; Inga Zerr; Jakob Matschke; Markus Glatzel
Journal:  Am J Neurodegener Dis       Date:  2014-12-05

8.  JC virus nucleotides 376-396 are critical for VP1 capsid protein expression.

Authors:  Laura C Ellis; Igor J Koralnik
Journal:  J Neurovirol       Date:  2014-08-21       Impact factor: 2.643

Review 9.  Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate.

Authors:  Thorsten Bartsch; Torge Rempe; Arne Wrede; Frank Leypoldt; Wolfgang Brück; Ortwin Adams; Axel Rohr; Olav Jansen; Christian Wüthrich; Günther Deuschl; Igor J Koralnik
Journal:  Ann Neurol       Date:  2015-07-31       Impact factor: 10.422

Review 10.  Immune surveillance and response to JC virus infection and PML.

Authors:  Sarah Beltrami; Jennifer Gordon
Journal:  J Neurovirol       Date:  2013-12-03       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.